The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Research works printed but not linked: 19
- Adelhorst, 1994, Structure-activity studies of GLP-1, J. Biol. Chem., 269, 6275, 10.1016/S0021-9258(17)37366-0 · DOI · Paper page
- Cottrell, 1992, Insulinotropic effect of GLP-1-(7–37) in non-insulin dependent diabetes mellitus patients: a study of dose and glucose dependency, Clin. Res., 40, 734A
- Deacon, 1995, Both subcutaneous and intravenously administered GLP-1 are rapidly degraded from the N-terminus in type-2 diabetic patients and in healthy subjects, Diabetes, 44, 1126, 10.2337/diabetes.44.9.1126 · DOI · Paper page
- Drejer, 1991, Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells, Diabetes, 40, 1588, 10.2337/diabetes.40.11.1488 · DOI
- Frohman, 1989, Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma, J. Clin. Invest., 83, 1533, 10.1172/JCI114049 · DOI · Paper page
- Gallwitz, 1994, Structure-activity characterization of glucagon-like peptide-1, Eur. J. Biochem., 225, 1151, 10.1111/j.1432-1033.1994.1151b.x · DOI
- Gallwitz, 1995, Binding characteristics of N-terminal GIP/GLP-1 hybrid peptides, Endocrinol. Metab., 2, 39
- Gefel, 1990, GLP-1 analogs: effects on insulin secretion and cAMP formation, Endocrinology, 126, 2164, 10.1210/endo-126-4-2164 · DOI
- Grandt, 1994, Is GLP-1-(9–36) amide an endogenous antagonist at GLP-1 receptors?, Digestion, 55, 302
- Hvidberg, 1994, Effect of GLP-1 on hepatic glucose production in healthy man, Metabolism, 43, 104, 10.1016/0026-0495(94)90164-3 · DOI · Paper page
- Jörnvall, 1981, Amino acid sequence and heterogeneity of gastric inhibitory polypeptide, FEBS Lett., 123, 205, 10.1016/0014-5793(81)80288-8 · DOI · Paper page
- Mojsov, 1992, Structural requirements for biological activity of GLP-1, Int. J. Pept. Protein Res., 40, 333, 10.1111/j.1399-3011.1992.tb00309.x · DOI · Paper page
- Pridal, 1995, Comparison of sandwich ELISA and RIA for detection of exogenous GLP-1-(7–36) amide in plasma, J. Pharm. Biomed. Anal., 13, 841, 10.1016/0731-7085(95)01312-9 · DOI
- Pridal, 1996, Glucagon-like peptide-1-(7–37) has a larger volume of distribution than glucagon-like peptide-1-(7–36) amide in dogs and is degraded more quickly in vitro by dog plasma, Eur. J. Drug Metab. Pharmacokin., 21, 51, 10.1007/BF03190278 · DOI
- Robberecht, 1988, Secretin receptors in human pancreatic membranes, Pancreas, 3, 529, 10.1097/00006676-198810000-00004 · DOI
- Rorstad, 1990, Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide, Mol. Pharmacol., 37, 971
- Schmidt, 1986, Characterization of the insulinotropic activity of fragments derived from gastric inhibitory polypeptide, Diabetologia, 29, 591A
- Suzuki, 1989, Comparison of the effects of various C-terminal and N-terminal fragment peptides of GLP-1 on insulin and glucagon release from isolated rat pancreas, Endocrinology, 125, 3109, 10.1210/endo-125-6-3109 · DOI
- Thorell, 1971, Enzymatic iodination of polypeptide with (125I) to high specific activity, Biochim. Biophys. Acta, 251, 363, 10.1016/0005-2795(71)90123-1 · DOI · Paper page
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“258 However, increasing research suggests that GLP-1(9 – 36) may have other physiological roles.”
BackgroundLambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Metadata
- Authors
- Knudsen, L. B., & Pridal, L.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 1996-12
- Volume
- 318
- Issue
- 2-3
- Pages
- 429-435
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2061202826
- Cited by
- 248
- References
- 5
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. https://app.cochat.ai/papers/10.1016/s0014-2999(96)00795-9
- The paper
- Knudsen, L. B., & Pridal, L. (1996). Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. European Journal of Pharmacology. https://doi.org/10.1016/s0014-2999(96)00795-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.